The impact of NOS3 gene polymorphism on papillary thyroid cancer susceptibility in patients undergoing radioiodine therapy

Thyroid cancer is the most common endocrine cancer in the world. Noting that the NOS3 gene polymorphism interferes with nitric oxide production, this study aims to identify and analyze the NOS3 gene polymorphism in the intron 4 region in patients with papillary thyroid cancer. A case-control study was conducted with 31 papillary thyroid cancer patients of both genders who underwent thyroidectomy and treatment with sodium iodide radiopharmaceutical (131I) compared with 81 control patients. Through papillary thyroid cancer, the results were observed, compiled, and analyzed using SPSS version 25.0. The significance level of 5% was adopted. Genotypic frequencies of healthy subjects were in the Hardy-Weinberg equilibrium ( P = 0.503). There was a significant genotypic difference between papillary thyroid cancer and healthy individuals ( P <0.001). The BB genotype conferred a protective factor for papillary thyroid cancer ( P <0.001, odds ratio (OR) 0.16; 95% confidence interval (CI) 0.06, 0.42), while the presence of the A allele appears to be a risk factor for papillary thyroid cancer ( P <0.001, OR 3.54; 95% CI 1.86, 6.73). The intron 4 polymorphism of the NOS3 gene was associated with susceptibility to papillary thyroid cancer. Thus, future research into the effects of this polymorphism is essential.

Download Full-text

BAX gene (−248 G > A) polymorphism in a sample of patients diagnosed with thyroid cancer in the Federal District, Brazil

The International Journal of Biological Markers ◽

10.1177/17246008211057576 ◽

2021 ◽

pp. 172460082110575

Author(s):

Ligia C.A. Cardoso-Duarte ◽

Caroline F. Fratelli ◽

Alexandre S.R. Pereira ◽

Jéssica Nayane Gomes de Souza ◽

Renata de Souza Freitas ◽

...

Keyword(s):

Thyroid Cancer ◽

Papillary Thyroid Cancer ◽

Protective Factor ◽

Federal District ◽

Genotypic Difference ◽

Control Group ◽

Nucleotide Polymorphisms ◽

Papillary Thyroid ◽

Genotype Frequencies ◽

Bax Gene

Introduction Papillary thyroid cancer corresponds to approximately 1% of all carcinomas; nevertheless, it is the most prevalent endocrine neoplasm in the world. Studies reveal that the BAX (−248 G > A) polymorphism may be associated with negative regulation of BAX gene transcription activity, causing a decrease in its protein expression. Objective The present study aimed to describe the genotype and allele frequencies of BAX single nucleotide polymorphisms (−248 G > A) (rs4645878) in the research patients, and to associate its presence with susceptibility to papillary thyroid cancer. Methods This case-control study was conducted with 30 patients with papillary thyroid cancer. For the evaluation of genetic polymorphisms, the polymerase chain reaction-restriction fragment length polymorphism technique was employed. Allele and genotype frequencies were estimated using the SPSS program, and significant associations were considered when p < 0.05. Results There was a significant genotypic difference between papillary thyroid cancer and the control group (p = 0.042). The GG genotype provided a protective factor for papillary thyroid cancer (p = 0.012, odds ratio (OR) = 0.313; confidence interval (CI) = 0.123–0.794). Likewise the G allele was a protective factor for papillary thyroid cancer (p = 0.009; OR = 0.360; CI = 0.163–0.793). The BAX gene polymorphism (−248 G > A) was associated with papillary thyroid cancer. Conclusion BAX (−248 G > A) GG genotype carriers, or at least one mutated allele, was associated with papillary thyroid cancer in the Brazilian population studied, and the G allele presence is considered a protective factor against papillary thyroid cancer occurrence.

Download Full-text

Low urinary iodine is a protective factor of central lymph node metastasis in papillary thyroid cancer: a cross-sectional study

World Journal of Surgical Oncology ◽

10.1186/s12957-021-02302-6 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Ziyang Zeng ◽

Kang Li ◽

Xianze Wang ◽

Siwen Ouyang ◽

Zimu Zhang ◽

...

Keyword(s):

Thyroid Cancer ◽

Papillary Thyroid Cancer ◽

Protective Factor ◽

Urinary Iodine ◽

Iodine Intake ◽

Clinicopathological Features ◽

Papillary Thyroid ◽

Central Lymph Node ◽

High Iodine ◽

Central Lymph

Abstract Background An abrupt increase of thyroid cancer has been witnessed paralleling the supplemented iodine intake in formerly iodine-deficient countries. And increased iodine intake has been linked to the rising incidence rate of papillary thyroid cancer (PTC). However, the correlation between iodine and clinicopathological features of PTC has not been well-characterized. This study aimed to investigate the associations between iodine intake and the clinicopathological features of PTC patients. Methods Three hundred and fifty-nine PTC patients who received surgical treatment in Peking Union Medical College Hospital from May 2015 to November 2020 were retrospectively reviewed. The associations between urinary iodine (UI), urinary iodine/creatinine ratio (UI/U-Cr), and the clinicopathological features of PTC were analyzed. Univariate and multivariate analysis were performed to investigate the relationship between UI level and central lymph node metastasis (CLNM). Results There were no significant differences in UI in different groups according to the variables studied, except that patients with CLNM had higher UI level than CLNM(−) patients. No associations were found between UI/U-Cr and clinicopathological features except variant subtypes (classic/follicular). After dividing patients into high-iodine group and low-iodine group, more patients were found to have CLNM in the high-iodine group (p = 0.02). In addition, younger age, larger tumor size, and classic variant were positively correlated with CLNM (p < 0.05). Univariate analysis showed that insufficient iodine intake (≤ 99 μg/L) was associated with decreased CLNM risk in PTC. And after defining insufficient iodine intake as ≤ 109 μg/L and above requirements as ≥ 190 μg/L, multivariate analysis showed that lower iodine was associated with CLNM in total population of PTC (OR 0.53, 95% CI 0.31–0.91) and in PTC < 1 cm (papillary thyroid microcarcinoma, PTMC) (OR 0.43, 95% CI 0.21–0.87). Conclusions Low iodine was a protective factor for CLNM in papillary thyroid cancer, particularly in those < 1 cm. These results indicated that iodine may not only be an initiator of tumorigenesis, but also a promoter of the development of PTC.

Download Full-text

Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer

Molecular Biology Reports ◽

10.1007/s11033-014-3169-7 ◽

2014 ◽

Vol 41 (5) ◽

pp. 3091-3097 ◽

Cited By ~ 7

Author(s):

Esra Çil ◽

Alkın Kumral ◽

Müge Kanmaz-Özer ◽

Pervin Vural ◽

Semra Doğru-Abbasoğlu ◽

...

Keyword(s):

Thyroid Cancer ◽

Gene Polymorphism ◽

Papillary Thyroid Cancer ◽

Interleukin 10 ◽

Papillary Thyroid

Download Full-text

Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND

Endocrine Related Cancer ◽

10.1530/erc-12-0309 ◽

2012 ◽

Vol 20 (1) ◽

pp. 13-22 ◽

Cited By ~ 27

Author(s):

Ali S Alzahrani ◽

Mingzhao Xing

Keyword(s):

Thyroid Cancer ◽

Neck Dissection ◽

Papillary Thyroid Cancer ◽

Tertiary Care ◽

Disease Recurrence ◽

Central Neck Dissection ◽

Central Neck ◽

Papillary Thyroid ◽

Cervical Lymph Nodes ◽

The Impact

The impact of metastasized cervical lymph nodes (CLN) identified on central neck dissection (CND) on the recurrence/persistence of papillary thyroid cancer (PTC) and the extent of CND needed to reduce recurrence/persistence have not been firmly established. To assess the impact of CLN metastasis andBRAFmutation on the recurrence/persistence of PTC and the potential ofBRAFmutation in assisting CND. Analyses of 379 consecutive patients with PTC who underwent thyroidectomy with (n=243) or without CND (n=136) at a tertiary-care academic hospital during the period 2001–2010 for their clinicopathological outcomes andBRAFmutation status. Increasingly aggressive tumor characteristics were found as the extent of CND was advanced following conventional risk criteria from non-CND to limited CND to formal CND. Disease recurrence/persistence rate also sharply rose from 4.7% to 15.7% and 40.5% in these CND settings respectively (P<0.0001). CLN metastasis rate rose from 18.0 to 77.3% from limited CND to formal CND (P<0.0001). An increasing rate ofBRAFmutation was also found from less to more extensive CND. A strong association of CLN metastasis andBRAFmutation with disease recurrence/persistence was revealed on Kaplan–Meier analysis andBRAFmutation strongly predicted CLN metastasis. CLN metastases found on CND are closely associated with disease recurrence/persistence of PTC, which are both strongly predicted byBRAFmutation. Current selection of PTC patients for CND is appropriate but higher extent of the procedure, once selected, is needed to reduce disease recurrence, which may be defined by combination use of preoperativeBRAFmutation testing and conventional risk factors of PTC.

Download Full-text

The Impact of Age and Gender on Papillary Thyroid Cancer Survival

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2011-2864 ◽

2012 ◽

Vol 97 (6) ◽

pp. E878-E887 ◽

Cited By ~ 96

Author(s):

J. Jonklaas ◽

G. Nogueras-Gonzalez ◽

M. Munsell ◽

D. Litofsky ◽

K. B. Ain ◽

...

Keyword(s):

Thyroid Cancer ◽

Papillary Thyroid Cancer ◽

Cancer Survival ◽

Papillary Thyroid ◽

Age And Gender ◽

And Gender ◽

The Impact

Download Full-text

Impact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 Years

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2014-3039 ◽

2015 ◽

Vol 100 (1) ◽

pp. 115-121 ◽

Cited By ~ 50

Author(s):

Mohamed Abdelgadir Adam ◽

John Pura ◽

Paolo Goffredo ◽

Michaela A. Dinan ◽

Terry Hyslop ◽

...

Keyword(s):

Thyroid Cancer ◽

Total Thyroidectomy ◽

Papillary Thyroid Cancer ◽

Extent Of Resection ◽

Stage I ◽

Papillary Thyroid ◽

Cancer Data ◽

Thyroid Lobectomy ◽

Extent Of Surgery ◽

The Impact

Abstract Context: Papillary thyroid cancer (PTC) patients <45 years old are considered to have an excellent prognosis; however, current guidelines recommend total thyroidectomy for PTC tumors >1.0 cm, regardless of age. Objective: Our objective was to examine the impact of extent of surgery on overall survival (OS) in patients <45 years old with stage I PTC of 1.1 to 4.0 cm. Design, Setting, and Patients: Adult patients <45 years of age undergoing surgery for stage I PTC were identified from the National Cancer Data Base (NCDB, 1998–2006) and the Surveillance, Epidemiology, and End Results dataset (SEER, 1988–2006). Main Outcome Measure: Multivariable modeling was used to compare OS for patients undergoing total thyroidectomy vs lobectomy. Results: In total, 29 522 patients in NCDB (3151 lobectomy, 26 371 total thyroidectomy) and 13 510 in SEER (1379 lobectomy, 12 131 total thyroidectomy) were included. Compared with patients undergoing lobectomy, patients having total thyroidectomy more often had extrathyroidal and lymph node disease. At 14 years, unadjusted OS was equivalent between total thyroidectomy and lobectomy in both databases. After adjustment, OS was similar for total thyroidectomy compared with lobectomy across all patients with tumors of 1.1 to 4.0 cm (NCDB: hazard ratio = 1.45 [confidence interval = 0.88–2.51], P = 0.19; SEER: 0.95 (0.70–1.29), P = 0.75) and when stratified by tumor size: 1.1 to 2.0 cm (NCDB: 1.12 [0.50–2.51], P = 0.78; SEER: 0.95 [0.56–1.62], P = 0.86) and 2.1 to 4.0 cm (NCDB: 1.93 [0.88–4.23], P = 0.10; SEER: 0.94 [0.60–1.49], P = 0.80). Conclusions: After adjusting for patient and clinical characteristics, total thyroidectomy compared with thyroid lobectomy was not associated with improved survival for patients <45 years of age with stage I PTC of 1.1 to 4.0 cm. Additional clinical and pathologic factors should be considered when choosing extent of resection.

Download Full-text